Tularik Press Releases
2004 Tularik Press Releases
Date Title
June 29, 2004 Tularik Announces Special Meeting of Stockholders to Approve Acquisition by Amgen
April 22, 2004 Tularik Reports 2004 First Quarter Financial Results
April 20, 2004 Tularik To Webcast Conference Call on First Quarter 2004 Financial Results
April 8, 2004 Tularik Postpones Annual Stockholders' Meeting
March 29, 2004 Amgen to Acquire Tularik for $1.3 Billion
March 8, 2004 Tularik and Sankyo Expand GPCR Drug Discovery Collaboration
March 5, 2004 Tularik to Present at the SG Cowen Securities 24th Annual Healthcare Conference
February 26, 2004 Tularik to Present at the Lehman Brothers Seventh Annual Global Healthcare Conference
February 12, 2004 Tularik Begins Phase 1 Clinical Trial of T71, a Novel Drug Candidate for the Treatment of Obesity
January 29, 2004 Tularik Reports Full Year 2003 Financial Results
January 21, 2004 Tularik to Webcast Conference Call on Full Year 2003 Financial Results
January 13, 2004 ADDING and REPLACING Tularik to Provide Clinical Development Update and 2004 Financial Guidance at JP Morgan Healthcare Conference
January 12, 2004 Tularik to Provide Clinical Development Update and 2004 Financial Guidance at JP Morgan Healthcare Conference
January 7, 2004 Tularik Initiates Phase 2 Clinical Trial of T131 in Type 2 Diabetes
January 6, 2004 Tularik to Present at the 22nd Annual JPMorgan Healthcare Conference
 
2003 Tularik Press Releases
Date Title  (click to view the full text PDF)
December 10, 2003 Tularik Initiates Phase 2 Clinical Trial of T487 in Psoriasis
December 9, 2003 Tularik and Sankyo Advance GPCR Drug Discovery Collaboration
December 4, 2003 Tularik Earns Milestone Payment from Eli Lilly and Company; Oral Factor Xa Inhibitor Enters Phase 2 Study for the Treatment of Thrombotic Diseases
November 17, 2003 Tularik Announces Underwriters' Exercise of Option to Purchase Additional Shares
November 11, 2003 Tularik Announces Pricing of Equity Offering
November 4, 2003 Tularik Announces Public Offering of Common Stock
October 22, 2003 Tularik Receives FDA Fast Track Designation for T67
October 16, 2003 Tularik Announces 2003 Third Quarter Financial Results
October 14, 2003 Tularik Achieves Milestones under Oncology Collaboration with Amgen; Two Compounds Selected for Advancement
October 7, 2003 Tularik To Webcast Conference Call on 2003 Third Quarter Financial Results
August 12, 2003 Tularik Receives Two National Cancer Institute Grants to Develop New Cancer Therapies
July 16, 2003 Tularik Announces 2003 Second Quarter Results
July 1, 2003 Tularik Receives $35 million from Amgen Following Hart-Scott-Rodino Clearance
May 21, 2003 Amgen and Tularik Announce Oncology Collaboration
April 30, 2003 Tularik Promotes Jin-Long Chen to Vice President, Biology
April 24, 2003 Tularik Reports 2003 First Quarter Financial Results
March 26, 2003 Researchers Discover New Breast Cancer Gene
March 25, 2003 Tularik Announces Initiation of Pivotal Trial of T67 for the Treatment of Hepatocellular Carcinoma; Global Development Program Underway
January 28, 2003 Tularik Reports Full Year 2002 Financial Results
January 27, 2003 Tularik Begins Phase 1 Clinical Trial of T131, a Novel Insulin-sensitizer for the Treatment of Type 2 Diabetes
 
2002 Tularik Press Releases
Date Title  (click to view the full text PDF)
December 11, 2002 Tularik Inc. Adopts Stockholder Rights Plan
November 18, 2002 Tularik Appoints Jack M. Anthony to Senior Vice President, Business and Commercial Development
November 12, 2002 Tularik Receives Milestone Payment from Eli Lilly and Company; Oral Factor Xa Inhibitor Enters Phase 1 Study for the Treatment of Thrombotic Diseases
October 18, 2002 Tularik Announces Public Offering of Common Stock
October 15, 2002 Tularik Announces 2002 Third Quarter Financial Results
October 8, 2002 Tularik Strengthens Management Team with Appointments in Clinical Development, Information Technology and Regulatory Affairs
September 26, 2002 Edward W. Holmes, M.D. Joins Tularik's Board of Directors
September 17, 2002 Tularik Begins Phase 1 Clinical Trial of T487, a Novel Drug Candidate for the Treatment of Inflammatory Diseases
August 26, 2002 Tularik Moving Forward with T67 Pivotal Trial Program in Patients with Hepatocellular Carcinoma
July 25, 2002 Tularik Announces 2002 Second Quarter Results
June 11, 2002 Tularik Begins GPCR Drug Discovery Collaboration with Sankyo
April 18, 2002 Tularik Announces 2002 First Quarter Financial Results
March 1, 2002 Tularik Promotes Chris H. Smith to Vice President, Human Resources
February 13, 2002 Tularik Reports Full Year 2001 Financial Results
January 9, 2002 Tularik and Medarex Announce Collaboration to Develop and Commercialize Human Therapeutic Antibodies
 
2001 Tularik Press Releases
Date Title  (click to view the full text PDF)
November 9, 2001 Tularik to Receive Award for Commitment to Employee Child Care
November 7, 2001 Tularik Receives Milestone Payment From Eli Lilly and Company; Anti-Thrombotic Research Collaboration Progresses to Next Stage
October 25, 2001 Tularik Announces 2001 Third Quarter Financial Results; Initiates Phase II Trial of Oral Anti-Cytomegalovirus Drug Candidate
October 9, 2001 Cumbre Establishes Scientific Advisory Board
September 26, 2001 Tularik and NeoGenesis Sign Drug Discovery Agreement
September 20, 2001 Cumbre Inc. Announces Major Financing
September 19, 2001 Craig Saxton, M.D. Joins Tularik's Board of Directors
July 25, 2001 Tularik corrects net loss; $21.1 million, or $0.44 per share, sted $23.0 million, or $0.47 per share
July 25, 2001 Tularik Announces 2001 Second Quarter Financial Results
July 12, 2001 Tularik Acquires Virtual Drug Screening Technology from U.K.'s Protherics
June 12, 2001 Tularik Announces Immune Disorders Initiative; Collaboration with ChemoCentryx Yields Promising Drug Leads
June 12, 2001 Tularik Granted U.S. Patents For Novel Human Kinases; IKK alpha and hRIP Play Roles In An Important Cell Signaling Pathway For Inflammation
May 31, 2001 Tularik Forms New Subsidiary To Develop Antibacterial and Antifungal Drugs in Texas; Tularik Texas Will Employ Novel Technology to Accelerate Antibiotic Development
May 11, 2001 Tularik Announces Abstracts For 2 Anti-Cancer Drugs at ASCO
April 25, 2001 Tularik Announces 2001 First Quarter Financial Results
April 16, 2001 Tularik Announces the Formation of German Subsidiary
February 14, 2001 Tularik Reports Full Year 2000 Financial Results
 
2000 Tularik Press Releases
Date Title  (click to view the full text PDF)
December 1, 2000 Tularik Discovers Genes Involved in Cholesterol Regulation
October 31, 2000 Tularik Announces 2000 Third Quarter Financial Results
August 14, 2000 Tularik Announces the Initiation of a Phase I Study for Anti-Cytomegalovirus Compound
July 27, 2000 Tularik Announces the Initiation of an Efficacy Study in Patients With Hepatocellular Carcinoma
July 25, 2000 Tularik Announces 2000 Second Quarter Financial Results
July 17, 2000 Tularik Announces the Initiation of Phase II Studies for Anti-Cancer Compound
June 29, 2000 Tularik Announces the Appointment of Two Prominent Scientists To Its Scientific Advisory Board
June 21, 2000 National Cancer Institute Supports Tularik Cancer Genomics
June 16, 2000 Tularik Names Juan Jaen, Ph.D., Vice President, Chemistry
May 31, 2000 Tularik and Japan Tobacco Announce Major Drug Discovery Alliance
April 25, 2000 Tularik Announces 2000 First Quarter Financial Results
April 12, 2000 Tularik Announces the Exercise of Over-Allotment Option for the Purchase of 375,000 Shares of Common Stock
March 31, 2000 Tularik and University of California, Berkeley Researchers Elucidate A New RNA Polymerase Protein Structure
March 22, 2000 Tularik Announces Pricing of Stock Offering
February 23, 2000 Tularik Inc. Files Registration Statement for Public Offering of Common Stock
February 15, 2000 Tularik Reports Full Year 1999 Financial Results